Background: The impact of lymphocyte-C-reactive protein ratio (LCR) on clinical outcomes has been reported in liver cancer such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), but the results remain inconsistent.Methods: We searched PubMed, Scopus, Web of Science, Embase and Cochrane Library databases for relevant studies evaluating the association of LCR with survival outcomes and clinicopathological parameters.Results: Eight studies with 4316 patients were included in this meta-analysis. Low LCR was significantly associated with poor overall survival, disease-free survival/relapse-free survival and disease progression clinicopathological parameters in patients with HCC or ICC.Conclusion: Low pretreatment LCR was an adverse prognostic indicator in patients with HCC or ICC. In addition, it was correlated with clinicopathological parameters indicating a higher stage of malignancy.
基金：
Government-funded clinical talent training project [361007]; Practical Teaching Reform and Research Project of Affiliated Hospital of Hebei University [2021P001]
第一作者机构：[1]Shenzhen Qianhai Shekou Free Trade Zone Hosp, Dept Radiol, Shenzhen 518067, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Shao Yong-jie,Yu Guo-dong,Zhang Xi,et al.Prognostic value of lymphocyte-C-reactive protein ratio in patients with liver cancer: a meta-analysis[J].BIOMARKERS IN MEDICINE.2023,17(10):497-507.doi:10.2217/bmm-2023-0270.
APA：
Shao, Yong-jie,Yu, Guo-dong,Zhang, Xi,Ran, Yu-ge&Li, Jing-hua.(2023).Prognostic value of lymphocyte-C-reactive protein ratio in patients with liver cancer: a meta-analysis.BIOMARKERS IN MEDICINE,17,(10)
MLA：
Shao, Yong-jie,et al."Prognostic value of lymphocyte-C-reactive protein ratio in patients with liver cancer: a meta-analysis".BIOMARKERS IN MEDICINE 17..10(2023):497-507
